Hepatocyte Growth Factor by Sakai Katsuya et al.
Hepatocyte Growth Factor













Hepatocyte Growth Factor 
 
 
Katsuya Sakai,1 Takayoshi Kinoshita,2 and Kunio Matsumoto1 
1Division of Tumor Dynamics and Regulation, 
Cancer Research Institute,  
Kanazawa University 
2Department of Biological Science,  
Graduate School of Science,  
Osaka Prefecture University 
 
Contact Information 
Kunio Matsumoto, Ph. D. 
Division of Tumor Dynamics and Regulation, 
Cancer Research Institute  
Kanazawa University 







amyotrophic lateral sclerosis, cancer stem cell, drug resistance, epithelial-mesenchymal 
interaction, growth factor, hepatocyte growth factor, liver regeneration, Met, metastasis, 




   
2 
Abstract 
Hepatocyte growth factor (HGF) exerts biological activity through the Met receptor tyrosine 
kinase. HGF plays essential roles in the embryonic development of the liver and placenta, 
and in the migration of myogenic precursor cells. In mature tissues, HGF plays roles in 
tissue protection and regeneration, including in the liver and kidney. HGF participates in 
invasion, metastasis, and drug resistance. Drug development targeting HGF-Met has been 
challenging. One focus has been the use of recombinant HGF as a biological drug and 
another has been the use of HGF-Met inhibitors for cancer treatment. Clinical trials using 
HGF or HGF-Met inhibitors are ongoing. 
 
 
   
3 
I. Introduction 
In 1984, hepatocyte growth factor (HGF) was reported to be a mitogenic protein for 
hepatocytes in primary culture. The primary structure of HGF became evident with cDNA 
cloning in 1989, when HGF was identified as a novel growth factor. A scatter factor was 
identified as a fibroblast-derived factor that enhances motility and the spreading of epithelial 
cells, and in 1991, it was found to be identical to HGF. Likewise, in 1991 the purification of 
a fibroblast-derived growth factor that targets a variety of epithelial cells independently 
revealed that it was identical to HGF. 
 
A tumorigenic met oncogene was initially isolated from chemically transformed human 
osteosarcoma cells in 1984. The primary structure of the met proto-oncogene clarified in 
1987 predicted that the Met is a receptor-type transmembrane tyrosine kinase. The Met was 
identified as a functional receptor for HGF in 1991. Following the molecular cloning of 
HGF and the identification of Met as a HGF receptor, diverse approaches revealed a variety 
of developmental, physiological, and therapeutic roles for HGF. Elucidation of the HGF-
Met pathway in tumor biology has facilitated the clinical development of different types of 
inhibitors for HGF-Met.  
 
II. Structure of HGF and the Met receptor 
HGF is a heterodimeric molecule composed of an α-chain and a β-chain, which are linked 
by one disulfide bridge (Fig. 1A). HGF is biosynthesized as a prepro-form of 728 amino 
acids, including a signal sequence and both α- and β-chains. After cleavage of a signal 
peptide of the first 31 amino acids, a single-chain HGF is further cleaved between Arg494 
and Val495, and this resulted in the formation of a two-chain mature HGF. Single-chain 
HGF is biologically inactive and processing into a two-chain form is coupled to its 
activation. Several serine proteases, mainly HGF activator, urokinase-type plasminogen 
activator, matriptase, and hepsin are responsible for the processing of HGF.  There are 
various forms of HGF such as those produced through the alternative splicing of HGF 
mRNA. A variant with five amino acids deleted in the first kringle domain is the second 
major form of HGF.  N-terminal smaller variants consisting of the N-terminal hairpin and 
the first kringle domains (designated NK1) and the N-terminal hairpin plus the first and 
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second kringle domains (designated NK2) are naturally biosynthesized variants of HGF, 
though expression of these variants is either very low or restricted in some cell lines.   
 
The Met receptor is composed of structural domains, the extracellular Sema, PSI  (the 
similar structure is found in the plexins, semaphorins and integrins) and IPT (a similar 
structure is found in the immunoglobulin-like fold shared by plexins and transcriptional 
factor) domains, the transmembrane domain, the intracellular juxtamembrane, and tyrosine 
kinase domains (Fig. 1B). HGF exhibits a 50% homology to an amino acid sequence in 
HGF-like protein. HGF and HGF-like protein contain four kringle domains in the α-chain. 
HGF-like protein specifically binds and activates Ron receptor tyrosine kinase, a family of 
the Met receptor.  
 
Binding of HGF to the Met receptor induces the phosphorylation of tyrosine residues in the 
activation loop of a tyrosine kinase domain, which results in the activation of tyrosine kinase 
and the subsequent phosphorylation of tyrosine residues in the C-terminal multifunctional 
docking site. Phosphorylation of the C-terminal tyrosine residues plays a critical role in both 
the direct and indirect recruitment of various intracellular signal transducers (Fig. 1B). 
Association of the adapter protein Gab-1 (Grb2-associated binding protein 1) with Met 
provides docking platforms for the further binding of signaling molecules, which leads to 
biological responses that are unique to the HGF-Met pathway. 
 
NK1 and NK2 bind the Met receptor as smaller N-terminal variants of HGF. NK1 serves a 
minimum set of domains that are responsible for high-affinity binding of HGF to the Met 
receptor, while β-chain binds to the Met with a lower affinity compared with the α-chain. 
The extracellular complex structure between HGF and Met was proposed using structural 
analyses such as small-angle X-ray scattering (Fig. 1C). NK1 and NK2 exhibit antagonistic 
activity on HGF-induced mitogenesis, while they function as agonists in terms of cell 
motility activity. NK4 is composed of an N-terminal hairpin and four kringle domains, and it 
binds to Met but does not activate Met, thereby being antagonistic to HGF.   
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Crystal structures have been revealed in selected domains of HGF and Met: NK1 and β-
chain in HGF; and, Sema, PSI, and tyrosine kinase domains in Met. The complex structures 
for NK1 and heparin, the β-chain of HGF and Sema, and the PSI domains of Met have also 
been determined. The crystal structures for the NK1 dimer, the complex structures of β-
chain and Sema + PSI domains, and tyrosine kinase domains are shown in Fig. 2. 
 
III. Biological activities 
HGF exhibits multiple biological activities in a wide variety of cells (Table. 1). HGF is 
mitogenic for differentiated epithelial cells (e.g., hepatocytes, renal tubular cells, bronchial 
and alveolar epithelial cells, gastric epithelial cells, and keratinocytes, etc.), vascular 
endothelial cells, mesenchymal/stromal cells (e.g., cardiomyocytes, articular chondrocytes, 
and osteoclast-like cells, etc.), and stem cells such as hepatic stem cells, hematopoietic 
progenitor cells, and skeletal satellite cells, as well as precursor cells that differentiate into 
myocytes. HGF as a “motogen” stimulates motility and migration in various cells. Among 
the multipotent characteristics of HGF, its morphogenic activity is unique. HGF induces 
branching tubulogenesis in epithelial cells, including renal tubular cells, mammary gland 
epithelial cells, and hepatic bile duct epithelial cells.   
 
HGF promotes cell survival in several cell types, including hepatocytes, renal epithelial 
cells, vascular endothelial cells, cardiac myocytes, and neurons.  HGF increases the activity 
and/or gene expression of proteases involved in the breakdown of extracellular matrix 
components, including urokinase-type plasminogen activator and matrix metalloproteases.  
Induction of these proteases plays an important role in the branching of tubulogenesis, as 
well as in migration and invasion of cells.  HGF induces the epithelial to mesenchymal 
transition of dermomyotome cells in embryos.   
 
IV. Developmental roles 
 
The essential roles of HGF in the development of mammalian fetal tissues have been 
defined via the targeted disruption of either HGF or the Met receptor gene using knockout 
mice that are embryonically lethal due to impaired organogenesis of the placenta and liver.  
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In the placenta, the number of epithelial trophoblasts in the labyrinthine layer is markedly 
reduced, leading to an impaired exchange of oxygen and nutrients between the maternal and 
embryonic blood streams.  The embryonic liver is reduced in size and shows extensive 
apoptotic cell death, indicating that hepatoblasts/hepatocytes in the embryonic liver require 
HGF for proliferation and/or survival.  
 
Activation of the HGF-Met pathway plays a decisive role in the generation of skeletal 
muscle that is derived from long-range migrating muscle precursor cells. In Met-/- mice, 
there is an impairment of the long-range migration of Met-positive myogenic precursor cells 
from the dermomyotome in the somite to limb buds and the diaphragm, which results in an 
absence of skeletal muscles of the limb and diaphragm. Since HGF is strongly expressed in 
the limb bud mesenchyme and septum transversum (which develops into the diaphragm), 
HGF provides spatially defined chemoattractant-like motogenic signals for the migration of 
myogenic precursor cells. A similar chemoattractant-like function of HGF was noted in the 
migration of myogenic precursor cells into the tongue.   
 
Epithelial-mesenchymal interactions mediate crucial aspects of normal development, 
affecting tissue induction, morphogenesis, and organogenesis. Involvement of HGF in 
epithelial-mesenchymal interactions and in the morphogenesis of organs has been revealed 
in organ culture experiments.  Cultured embryonic organs undergo morphogenic steps that 
mimic their development in vivo.  In organ cultures, neutralizing the anti-HGF antibody 
inhibits both the morphogenesis of developing lung epithelia and the branching 
tubulogenesis of developing epithelia in kidneys and mammary glands.  In tooth germ 
culture, inhibition of HGF expression impairs the morphogenesis of tooth epithelium. Thus, 
HGF is known to be a mesenchymal-derived paracrine factor that supports the 
morphogenesis of developing epithelia during the organogenesis of the lung, kidney, and 
tooth. 
 
In the nervous system, HGF has chemoattractant-like functions.  Developing axons can be 
guided to their targets by diffusible molecules and factors bound to the cell surface that act 
either as chemoattractants or repellents.  Transplanted limb buds attract motor axons in 
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amphibians and birds. In a similar manner, explanted mouse limb bud mesenchyme attracts 
the axons of motor neurons.  HGF has been identified as a chemoattractant factor that is 
derived from the limb bud mesenchyme.  The developmental and morphogenic roles of HGF 
are summarized in Table 2.   
 
V. Physiological functions 
Regeneration of the liver is a dramatic phenomenon in higher animals. When 70% of the 
liver is resected, the cells in the remaining liver rapidly proliferate, and the original liver 
mass is restored within a week. HGF was initially implicated as a hepatotrophic factor that 
enhances liver regeneration, and the hepatotrophic role of HGF has been definitively 
demonstrated in a variety of experimental hepatic disease models. Likewise, HGF plays 
physiological roles in the regeneration and/or protection of various tissues, as demonstrated 
in different types of disease models in different tissues (Table 2). 
 
A conditional knockout of the Met gene in mice has helped to define the roles of the HGF-
Met pathway in tissue protection and repair (Table 3). Hepatocytes subjected to selective 
loss of functional Met are highly susceptible to cell death even after mild liver injury, 
indicating that the anti-apoptotic activity of HGF plays a role in protection of the liver. 
Liver- or hepatocyte-specific Met-/- mice have shown delayed liver regeneration associated 
with persistent inflammatory reaction, and are susceptible to fibrotic change in the liver. 
After bile duct ligation, hepatocyte-specific Met-/- mice were more susceptible to chronic 
inflammation and fibrotic change compared with control mice. The effects shown by these 
liver- or hepatocyte-specific Met-/- mice indicate the physiological roles of the HGF-Met 
pathway in the protection, regeneration, anti-inflammation, and anti-fibrosis of the liver. 
 
In addition to the liver, characterizations of a variety of conditional Met knockout mice 
indicate that the HGF-Met pathway plays important roles in the regeneration, protection, and 
homeostasis in various cells and tissues (Table 3). For instance, a loss of functional Met in 
renal tubules had no appreciable defect in renal function, but when tubular cell-specific Met-
/- mice were subjected to renal injury, they displayed a higher serum creatinine, more severe 
morphologic lesions, and increased apoptosis compared with control mice. 
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In podocyte-specific Met-/- mice, no pathology was seen, but the mice developed more 
severe podocyte apoptosis and albuminurea in comparison with control mice when subjected 
to toxic renal injury for podocytes. Disruption of the Met gene in epidermal keratinocytes 
has clearly demonstrated an indispensable role for the HGF-Met pathway in skin wound 
healing. Because migration of keratincocytes post-wounding is almost completely impaired 
in Met-/- keratinocytes, re-epithelialization was severely suppressed, indicating a definitive 
role for the HGF-Met pathway in skin wound healing. 
 
Increased HGF levels in sera or tissue fluid have been noted in patients with distinct types of 
diseases, including acute hepatitis, fulminant hepatitis, acute renal rejection after 
transplantation, pneumonia, cardiac infarction, severe acute pancreatitis, and Crohn’s, 
Huntington’s, Parkinson’s, and Alzheimer’s diseases.  Increased HGF levels in sera or tissue 
fluids are likely to reflect physiological responses to tissue and cellular damage.   
 
VI. Tumorigenesis and tumor progression 
Aberrant activation of Met is associated with tumor development or progression to a tumor 
with malignant characteristics. Overexpression of Met through transcriptional upregulation 
has been noted in several cancers, including thyroid, ovarian, pancreatic, prostatic, renal, 
hepatocellular, breast, and colorectal. Overexpression of Met through gene amplification 
has been found in cancers with highly invasive and malignant characteristics, including 
gastric and esophageal carcinomas, medulloblastoma, and non-small-cell lung carcinomas 
(NSCLC). Autocrine and paracrine activation of Met through overexpression of HGF has 
been noted in breast cancer, glioblastoma, rhabdomyosarcoma, osteosarcoma, and in 
NSCLC with acquired and intrinsic resistance to EGFR tyrosine kinase inhibitors. 
 
Missense mutations in the Met gene are causative genetic disorders in inherited, and in some 
sporadic, papillary renal carcinomas. Mutations found in papillary renal carcinomas are 
located in the tyrosine kinase domain of the Met receptor, and these Met mutations are likely 
to be gain-of-function mutations. In addition to papillary renal carcinoma, missense 
mutations in the Met gene have been found in different types of cancers, including lung 
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cancer, hepatocellular carcinoma, and gastric cancer in the Sema, IPT, juxtamembrane, and 
tyrosine kinase domains. 
 
Although aberrant activation of the Met is involved in the tumorigenic transformation of 
cells, the Met activation in tumor cells participates in the progression to malignant tumors 
that is characterized by invasiveness, metastatic behavior, and/or resistance to anticancer 
therapies. Cell-cell adhesion, cell-extracellular matrix association, proteolytic breakdown of 
the extracellular matrix, and cellular locomotion regulate the invasiveness of tumor cells. 
Because HGF affects these processes, HGF exhibits profound effects on the invasive 
behavior of a wide variety of tumor cells. Gene transfer experiments that involve autocrine 
activation of the Met receptor confer invasive and metastatic behavior in cancer cells. 
Although tumor-stromal interaction closely affects the invasive and metastatic behavior of 
carcinoma cells, HGF is a key stromal-derived factor that confers invasive characteristics in 
cancer cells in a variety of tumor microenvironments.     
 
Gefitinib and erlotinib, selective inhibitors for epidermal growth factor receptor (EGFR) 
tyrosine kinase, show favorable responses in NSCLC, particularly those expressing 
activating mutations in EGFR. However, almost without exception, the patients develop 
acquired resistance to EGFR tyrosine kinase inhibitors within several years. Met gene 
amplification has been detected in ~20% of patients with acquired resistance to gefitinib or 
erlotinib. HGF induces resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung 
cancer. High-level expression of HGF has been noted in 60 and 19% of patients with 
acquired and intrinsic resistance to EGFR tyrosine kinase inhibitors, respectively. In 
addition to EGFR tyrosine kinase inhibitors, HGF in a tumor microenvironment has 
conferred resistance to BRAF inhibitors in malignant melanoma and breast cancer. 
Collectively, the over-expression of HGF in cancer cells and/or stromal cells and Met 
overexpression in cancer cells closely participate in the resistance to several molecular 
targeted drugs.  
 
Pathological and clinical studies have indicated that the presence of hypoxic regions within 
neoplastic lesions correlates with a poor prognosis and an increased risk of the 
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development of distant metastases. A hypoxic condition has been known to induce the 
transcriptional activation of the Met receptor gene and the subsequent amplification of 
HGF-Met signaling, thereby increasing the invasiveness of cancer cells. A connection 
between hypoxia and the Met receptor seems to explain why hypoxia often correlates with 
invasive and metastatic behavior. 
 
The concept of a cancer stem cell proposes that tumors are organized in a cellular 
hierarchy, and they are maintained by a subpopulation of cells displaying stem cell 
characteristics, i.e., self-renewal and differentiation that contributes to cellular 
heterogeneity and tumor bulk. The HGF-Met pathway plays an important role in 
regulating the stemness and invasiveness of cancer stem cells. In a brain tumor model, 
cancer stem cells aggressively invaded surrounding normal brain tissues. Met gene 
expression was much higher in tumor-initiating cells, compared to non-tumor-initiating 
cells. Strong Met tyrosine phosphorylation was seen in the population of the cancer stem 
cells, and HGF enhanced the invasion of the brain tumor-initiating cells. In colon 
adenocarcinomas, myofibroblast-derived factors, specifically HGF, activated Wnt/β-
catenin signaling and subsequently the clonogenicity of colon cancer stem cells. Therefore, 
together with Wnt activity, HGF plays a role in maintaining the stemness of colon cancer 
stem cells through tumor-stromal interaction in the microenvironment. The promotion of 
stemness by HGF has also been noted in cases that include human prostate cancer and 
basal-like breast cancer. 
 
VII. Therapeutic approaches using HGF 
Based on the evidence that activation of the Met receptor leads to tissue protection and 
repair against tissue injury, but also to invasive and metastatic progression of cancer cells in 
tumor tissues, two distinct therapeutic approaches can be considered: one is application of 
HGF, i.e., Met-agonist, for treatment of organ injuries; and the other is application of 
inhibitory molecules against the HGF-Met pathway to inhibit cancer invasion and 
metastasis.   
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Experiments to explore the therapeutic potential of HGF in the treatment of diseases have 
been performed in various disease models in different tissues (Table 2).  Administration of 
human recombinant HGF into mice or rats stimulates the proliferation of hepatocytes after 
liver insult caused by partial hepatectomy or hepatotoxins.  Through its anti-apoptotic 
action, HGF has been used to abrogate the onset of acute hepatitis and fulminant hepatic 
failure.  Likewise, the administration of HGF has accelerated tissue regeneration and/or 
attenuated tissue injury in other organs. HGF has suppressed the onset of acute renal failure 
caused by the administration of nephrotoxic drugs or renal ischemia.  HGF administered to 
rats with cardiac ischemia-reperfusion injury has reduced the extent of apoptosis in cardiac 
myocytes, thereby reducing the infarcted area.  
 
Chronic inflammatory diseases are characterized by fibrotic changes in tissues, including 
liver cirrhosis, chronic renal failure, lung fibrosis, and cardiomyopathy.  These fibrotic 
diseases are progressive and currently incurable.  Administration of HGF into rats with liver 
cirrhosis has been used to decrease the accumulation of hepatic extracellular matrix 
components, thereby abrogating the mortality rate due to hepatic dysfunction.  HGF has 
prevented renal fibrosis and the concomitant renal dysfunction in models of chronic renal 
failure or renal fibrosis.  Although mechanisms responsible for the anti-fibrotic action of 
HGF are not fully understood, HGF suppresses the expression of transforming growth 
factor-β, a key growth factor during the onset of tissue fibrosis, while HGF enhances the 
protease activities responsible for the degradation of extracellular matrix components, 
including matrix metalloproteinases.  
 
The neurotrophic actions of HGF have been expanded to include therapeutic approaches for 
the treatment of injury or diseases of the nervous system. An infusion of HGF into the brain 
has been used to prevent neuronal death in the hippocampus and in the cerebral cortex. 
Intrathecal administration of HGF has suppressed disease progression and prolonged the life 
span in rat models for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative 
disorder characterized by the progressive loss of motor neurons and the degeneration of 
motor axons. Likewise, the intrathecal administration of HGF has been used to promote 
functional recovery after spinal cord injury in the common marmoset. 
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The efficacy and safety of the intramuscular injection of a naked plasmid encoding the 
human HGF gene was investigated in patients with critical limb ischemia in a multicenter, 
randomized, double-blind, placebo-controlled trial. HGF achieved a significantly higher 
improvement rate than the placebo, including the improvement of resting pain and a 
reduction in ulcer size. In this instance, HGF gene therapy improved the quality of life, 
without major safety problems. Thus, HGF gene therapy has been found to be safe and 
effective for critical limb ischemia. A phase-I clinical trial of recombinant HGF protein for 
the treatment of patients with acute kidney injury has been completed and is ongoing for the 
treatment of patients with ALS.  
 
VIII. Drug development for cancer treatment 
Several distinct approaches to inhibition of the HGF-Met pathway have been demonstrated, 
including small synthetic inhibitors for Met tyrosine kinase, ribozymes, small-interfering 
RNA, neutralizing monoclonal antibodies, soluble forms of Met, antagonistic domains in 
HGF, and uncleavable single-chain HGF. Among these approaches, the development of 
small-molecule Met tyrosine kinase inhibitors and monoclonal antibody against HGF or Met 
progressed earlier than the others, and several inhibitors against HGF-Met either are 
currently in clinical development or is already being marketed (Table 4).  
 
Crizotinib was originally developed as a Met tyrosine kinase inhibitor, and it strongly 
inhibits anaplastic lymphoma kinase (ALK). Because the fusion oncogene EML4-ALK has 
been effective for a distinct clinicopathologic subset of patients with non-small cell lung 
cancer (NSCLC), crizotinib has been approved for the treatment of these patients who also 
have demonstrated an ALK mutation.  
 
MetMAb is a humanized monovalent monoclonal antibody against Met receptor that blocks 
the binding of HGF to the Met, while rilotumumab and SCH900105 are humanized 
monoclonal antibodies against HGF. Among small molecule tyrosine kinase inhibitors, 
some have a relatively higher selectivity to Met while others are multi-target tyrosine kinase 
inhibitors.  Effectiveness, target cancer, and advantages/disadvantages of each of these 
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therapeutic tools (small molecule Met tyrosine kinase inhibitors, anti-HGF, or anit-Met) will 
be clarified in further clinical trials. 
 
IX. Perspectives 
Earlier studies on the biological and physiological functions of HGF as motogenic and 
morphogenic factors during development and tissue regeneration/protection have been 
definitively demonstrated in genetic mouse models lacking functional HGF or Met. 
Conditional knockout mice lacking functional Met in selective cells/tissues have revealed 
not only implicated functions from earlier studies but also unpredicted functions from earlier 
studies. On the other hand, decreased Met function has been found to increase the risk of 
developing autism spectrum disorders in extensive analysis among autism families. 
Selective deletion of functional Met in selective regions/neurons in the forebrain in mice 
showed changes associated with the autism spectrum disorder. Thus, a large-scale gene 
analysis in humans will further clarify the relationship between aberrant HGF-Met function 
and disorders, and the corresponding animal models will explore new therapeutic 
approaches. 
 
Progress during the past decade in the development of the potential therapeutic use of Met 
activators (HGF or HGF gene) and Met inhibitors (Met tyrosine kinase inhibitors, antibodies 
against HGF/Met) should be emphasized. The use of recombinant HGF and the HGF gene 
has entered into the development phase in clinical trials. Several HGF-Met inhibitors are in 
clinical trials for the treatment of patients with malignant tumors and some of them have 
been successfully marketed. Clinical study on abnormal HGF-Met function in the 
pathogenesis of malignant tumors will explore further therapeutic uses of HGF-Met 
inhibitors for the treatment of patients with malignant tumors.   
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Table 1. Target cell types of HGF 
 
 
Tissue type Target cell type 
    
Hepato-bilialy and pancreas  hepatocyte 
 hepatoblast 
 bile duct epithelial cell 
 pancreatic β-cell 
 
Gastrointestinal gastric epithelial cell 
 intestinal mucosal epithelial cell 
 
Kidney renal tubular cell 
 podocyte 
 
Lung bronchial epithelial cell 
 alveolar type II epithelial cell 
 
Nervous  neuron (hippocampal neuron, cerebral cortex neuron, 
midbrain dopaminergic neuron, cerebellar granular 
neuron, motor neuron, thalamic neuron, sensory 
neuron, sympathetic neuron, parasympathetic neuron, 
subventiricular zone neural stem-like cell), Schwann 
cell, astrocyte, oligodendrocyte progenitor cell 
 
Cardiovascular and lymphatic  cardiomyocyte (in hypoxic condition) 
 vascular endothelial cell 
 lymphatic vessel cell 
 
Hematopoietic and immune dendritic cell 
 hematopoietic stem/progenitor cell 
 monocyte-osteoclast 
 macrophage (conditionally) 
 
Skin and eye keratinocyte 
 melanocyte 
 hair bulb keratinocyte 
 corneal epithelial cell 
 
Muscle, bone, and joint muscle satellite cell 
 myogenic precursor cell 
 articular chondrocyte 
 
Glands mammary gland epithelial cell 
 submandibular gland epithelial cell 
 salivary gland epithelial cell 
 prostate epithelial cell 
 thyroid cell 
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